Ovid Therapeutc (NASDAQ:OVID) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price objective of $21.00 for the company, according to Zacks. Zacks has also assigned Ovid Therapeutc an industry rank of 106 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised Ovid Therapeutc from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/23/brokerages-set-21-00-target-price-for-ovid-therapeutc-ovid.html.

In other Ovid Therapeutc news, CEO Jeremy M. Levin bought 15,334 shares of the stock in a transaction on Friday, August 25th. The stock was purchased at an average price of $7.15 per share, with a total value of $109,638.10. Following the completion of the purchase, the chief executive officer now owns 4,601,529 shares in the company, valued at $32,900,932.35. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Several large investors have recently added to or reduced their stakes in OVID. Bank of New York Mellon Corp bought a new stake in shares of Ovid Therapeutc during the second quarter worth about $135,000. TIAA CREF Investment Management LLC bought a new stake in shares of Ovid Therapeutc during the second quarter worth about $142,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Ovid Therapeutc during the second quarter worth about $153,000. OxFORD Asset Management LLP bought a new stake in shares of Ovid Therapeutc during the second quarter worth about $189,000. Finally, Citadel Advisors LLC bought a new stake in shares of Ovid Therapeutc during the second quarter worth about $204,000. Institutional investors own 32.44% of the company’s stock.

Ovid Therapeutc (NASDAQ OVID) traded down 1.08% during midday trading on Monday, hitting $7.32. 23,506 shares of the stock traded hands. Ovid Therapeutc has a 12-month low of $5.28 and a 12-month high of $15.93. The stock’s market capitalization is $180.08 million. The firm’s 50 day moving average is $8.61 and its 200-day moving average is $9.96.

Ovid Therapeutc (NASDAQ:OVID) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.09). On average, analysts anticipate that Ovid Therapeutc will post ($3.88) EPS for the current fiscal year.

About Ovid Therapeutc

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Get a free copy of the Zacks research report on Ovid Therapeutc (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.